🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System

Recruitingn/aAges 18 Years - anyAllNanjing Medical University
NCT06824714 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Large vessel vasculitis (LVV) causes vascular inflammation, leading to serious complications such as aneurysm formation and stroke. It is difficult to identify the inflammation of the vessel wall by the current imaging methods, thus affecting the timing of treatment and selection of treatment options. Improved examination methods to determine disease activity are highly needed to guide treatment.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Clinically suspected or confirmed LVV and willing to undergo PET/MRA 2. Compliance with long-term follow-up 3. Sign informed consent. Exclusion Criteria: 1. Patients with other serious cardiovascular and cerebrovascular diseases, malignant tumors, infectious diseases, severe renal insufficiency. 2. Severe mental disorders, severe claustrophobia unable to cooperate with the examination. 3. Patients equipped with cardiac pacemaker, artificial heart valve, ferromagnetic vascular clamp after vascular surgery, aneurysm clamp, artificial cochlea, insulin pump and other drug dosage control devices, steel nail plate and other metal internal fixation, artificial joint, electronic eye, artificial eye. 4. Allergic to contrast medium. 5. Pregnant or lactating women. Withdrawal criteria: 1. Any exclusion criteria emerged during patient follow-up. 2. Voluntarily withdrew from the study.
💊

What it tests

  • glucocorticoid, immunosuppressants, targeted therapy
📍

Where

1 site
Department of Rheumatology and Immunology, Jiangsu Province Hospital, Nanjing Medical University
Nanjing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy